Roche's Perjeta has been launched today in the UK for use in women with HER2-positive breast cancer before surgery – but, as with many new cancer drugs, access to treatment is uncertain.
Roche subsidiary, Genentech, has announced that the US FDA has accepted its supplemental Biologics License Application (sBLA) for the use of a Perjeta (pertuzumab) regimen before surgery ...
In addition, with the launch of Perjeta in 2012, Kadcyla in 2013, and Phesgo (a subcutaneous coformulation of Herceptin and Perjeta) in 2020, Roche has somewhat refreshed its breast cancer franchise.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback